Assembly Biosciences (ASMB) Non-Current Assets (2010 - 2026)
Assembly Biosciences (ASMB) posted quarterly Non-Current Assets of $2.9 million for Q1 2026, down 17.05% year-over-year from $3.5 million in Q1 2025, and down 4.8% quarter-over-quarter from $3.0 million in Q4 2025.
Assembly Biosciences (ASMB) Non-Current Assets (2010 - 2026) Analysis & Trends
Assembly Biosciences' Non-Current Assets history runs 17 years deep, the most recent figure standing at $2.9 million for Q1 2026.
- In Q1 2026, Non-Current Assets fell 17.05% year-over-year to $2.9 million; the TTM figure through Mar 2026 stood at $12.4 million (up 7.23% YoY), while the FY2025 annual figure was $3.0 million, down 17.03% from the prior year.
- Non-Current Assets for Q1 2026 stood at $2.9 million, down from $3.0 million in the prior quarter.
- The five-year high for Non-Current Assets was $32.0 million in Q1 2022, with the low at $2.0 million in Q3 2023.
- The 5-year median for Non-Current Assets is $3.2 million (2025), against an average of $5.9 million.
- The sharpest annual moves came in 2023 and 2025: Non-Current Assets slumped 89.45% in 2023, then jumped 55.44% in 2025.
- Assembly Biosciences' Non-Current Assets stood at $4.8 million in 2022, then tumbled by 37.1% to $3.0 million in 2023, then grew by 20.72% to $3.7 million in 2024, then fell by 17.03% to $3.0 million in 2025, then declined by 4.8% to $2.9 million in 2026.
- Business Quant data shows ASMB's Non-Current Assets at $2.9 million in Q1 2026, $3.0 million in Q4 2025, and $3.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Assembly Biosciences | 670.88 Mn | 350.52 Mn | - | 2.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.85 Mn |
| Mar 31, 2026 | 2.90 Mn |
| Dec 31, 2025 | 3.04 Mn |
| Sep 30, 2025 | 3.19 Mn |
| Jun 30, 2025 | 3.31 Mn |
| Mar 31, 2025 | 3.49 Mn |
| Dec 31, 2024 | 3.67 Mn |
| Sep 30, 2024 | 2.05 Mn |
| Jun 30, 2024 | 2.39 Mn |
| Mar 31, 2024 | 2.72 Mn |
| Dec 31, 2023 | 3.04 Mn |
| Sep 30, 2023 | 1.96 Mn |
| Jun 30, 2023 | 2.50 Mn |
| Mar 31, 2023 | 3.37 Mn |
| Dec 31, 2022 | 4.83 Mn |
| Sep 30, 2022 | 6.44 Mn |
| Jun 30, 2022 | 19.15 Mn |
| Mar 31, 2022 | 31.95 Mn |
| Dec 31, 2021 | 36.86 Mn |
| Sep 30, 2021 | 60.75 Mn |